Adding Regorafenib in First-Line ‘Promising’ in Gastric Cancer
Adding regorafenib (Stivarga) to a standard first-line chemoimmunotherapy regimen for HER2-negative metastatic esophagogastric cancer demonstrated “promising” activity in a single-arm phase II study, according to researchers. Among 35 evaluable patients treated with the tyrosine kinase inhibitor (TKI) plus nivolumab (Opdivo) and FOLFOX chemotherapy, 25 (71%, 95% CI 54-85) remained progression free at 6 months, thus […]
FDA Greenlights New First-Line Regimen in Bladder Cancer
The FDA gave accelerated approval to enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) as first-line treatment for certain patients with locally advanced or metastatic urothelial cancer, the agency announced on Monday. Specifically, the combination is indicated for those who are ineligible for cisplatin-containing chemotherapy, and the approval marks the first anti-PD-1/antibody-drug conjugate combination for this patient […]
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC
SAN FRANCISCO — First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful survival benefits in advanced renal cell carcinoma (RCC). An update of the CheckMate 9ER trial, which compared the immune checkpoint inhibitor/tyrosine kinase inhibitor (TKI) doublet with the TKI sunitinib (Sutent), showed that after 44 months of median follow-up, median progression-free survival […]
SGLT2 Inhibitors, GLP-1 RAs Not Cost-Effective as First-Line T2D Agents
Although using newer classes of diabetes drugs as first-line therapy can boost life expectancy, this strategy can be quite pricey, according to a cost-effectiveness study. Compared with traditional first-line metformin, first-line SGLT2 inhibitors cost $43,000 more over a lifetime, and first-line GLP-1 receptor agonists cost $49,000 more, reported Neda Laiteerapong, MD, MS, of the University […]
Which Antibiotic Is Best for An Ear Infection? Treatment, Complications
What are ototopical antibiotics? Ototopical antibiotics are applied as the first-line offense against middle ear infection. Ototopical antibiotics are medications administered topically in the ear for treating middle ear infections. Ototopical antibiotics are usually the first-line treatment for recurrent bacterial ear infections, in the absence of systemic infection. Ear infections are more common in children, […]
Another China-Developed PD-1 Inhibitor Makes Its Case in NSCLC
Adding the investigational PD-1 checkpoint inhibitor toripalimab to chemotherapy in first-line significantly improved progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients without EGFR/ALK mutations, according to results from a study conducted in China. Median PFS improved from 5.6 months with chemotherapy alone to 8.4 months with the toripalimab-based combination (HR 0.49, 95% […]
Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC
Adding PARP inhibition to first-line abiraterone (Zytiga) reduced the risk of radiographic progression or death in metastatic castration-resistant prostate cancer (mCRPC), a pair of phase III studies showed. In PROpel, patients who received olaparib (Lynparza) along with abiraterone plus prednisone had a roughly 8-month improvement in median radiographic progression-free survival (rPFS) versus those assigned placebo […]
Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancer
Adding the CDK 4/6 inhibitor ribociclib (Kisqali) to a first-line hormonal treatment prolonged survival by more than 1 year in postmenopausal women with HR-positive/HER2-negative (HR+HER2-) advanced breast cancer, according to results from the MONALEESA-2 trial. Final overall survival (OS) results showed that patients treated with ribociclib plus the aromatase inhibitor (AI) letrozole (Femara) achieved a […]